UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2021
SYNEOS HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36730 | 27-3403111 |
(State or other jurisdiction | (Commission | (IRS Employer |
1030 Sync Street Morrisville, North Carolina | 27560-5468 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (919) 876-9300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Class A Common Stock, |
| SYNH |
| The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
On January 21, 2021, Syneos Health, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Filing”) to report, among other items, the appointment of Donna Kralowetz as the Company’s Chief Accounting Officer and principal accounting officer, in each case effective January 27, 2021. Pursuant to Instruction 2 to Item 5.02 of Form 8-K, this Form 8-K/A is being filed solely to report information called for in Item 5.02(c)(3) of Form 8-K that had not been determined at the time of the filing of the Original Filing.
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 2, 2021, the Compensation and Management Development Committee of the Board of Directors of the Company approved, among other changes, a one-time $100,000 grant of time-based restricted stock units pursuant to the Company’s 2018 Equity Incentive Plan to Ms. Kralowetz in connection with her appointment as the Company’s Chief Accounting Officer. The award will vest in three approximately equal annual installments on the first three anniversaries of the date of grant, subject to her continued employment with the Company.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
| SYNEOS HEALTH, INC. | |
|
|
|
|
|
Date: | March 8, 2021 | By: | /s/ Jason Meggs | |
|
|
| Name: | Jason Meggs |
|
|
| Title: | Chief Financial Officer (Principal Financial Officer) |